Close this search box.

Sensus Healthcare to Participate in Two Upcoming Investor Conferences

August 27, 2018

BOCA RATON, Fla., Aug. 27, 2018Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), today announced that Joe Sardano, President and Chief Executive Officer, will participate at two investor conferences in September 2018, as follows:

Annual B. Riley FBR Healthcare Conference


Tuesday, September 4, 2018


One-on-one meetings only


New York Marriott East Side in New York City

H.C. Wainwright 20th Annual Global Investment Conference


September 4-6, 2018


Company presentation


Thursday, September 6, 2018 at 11:40 a.m. Eastern time


St. Regis New York Hotel in New York City

Mr. Sardano’s presentation at the H.C. Wainwright 20th Annual Global Investment Conference will be webcast live and available for replay in the Investor Relations section of the Company’s website at

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit

LHA Investor Relations
Kim Sutton Golodetz
(212) 838-3777
[email protected]

Cision View original content:

SOURCE Sensus Healthcare